Nigerian epidemiologist and WHO official
Scientists at Oxford have begun Phase I trials of a ChAdOx BDBV vaccine for Bundibugyo Ebola in healthy UK adults, with 620,000 doses stockpiled and partnerships for African trials. The trial monitors safety and immune response for a year as the outbreak expands in the Democratic Republic of Congo.